Barton Gold to Present at Precious Metals Summit Zurich

Adelaide, Australia--(Newsfile Corp. - October 23, 2023) - Barton Gold (FSE: BGD3) (ASX: BGD) is pleased to announce its participation at the 2023 Precious Metals Summit Zurich where it will be delivering a live corporate update on November 13th at 11:15 AM CET.

We invite our shareholders, and all interested parties to view the live webcast, accessible via the organizers website, www.precioussummit.com.

A replay will be available following the presentation via the Precious Metals Summit Conferences website.

For more information: https://www.precioussummit.com/event/2023-precious-metals-summit-zurich/

About Barton Gold

Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold exploration company with a total attributable 1.3Moz Au JORC Mineral Resources endowment (40.6Mt @ 1.0 g/t Au), a pipeline of advanced exploration projects and brownfield mines, and 100% ownership of the only regional gold mill in the central Gawler Craton of South Australia.

About Precious Metals Summit Conferences:

Precious Metals Summit Conferences is a premier organizer of institutional investor conferences, renowned for bringing professional investors, portfolio managers and sell-side analysts together with developers and explorers from around the globe. Annual Precious Metals Summit events in Zurich and Beaver Creek are universally recognized as top destinations for resource investors and growth-oriented companies. The Summit also manages the official One on One Meetings Program at PDAC in Toronto. Please visit www.precioussummit.com for more details.

For further information:

Alexander Scanlon
MD & CEO
+61 425 226 649
[email protected]

For additional information contact [email protected] or visit:

www.precioussummit.com
www.linkedin.com/company/precioussummit/

You May Also Be Interested In

• Thor Explorations Announces Third Quarter 2026 Financial and Operating Results, for the Three Months Ending September 30, 2026
• Growth in the Q3 Revenue, Reaching CHF 310.2 Million, an Increase of 10.2% at Constant Exchange Rates
• Iksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASH